Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...

BRISBANE, Calif. & NEW YORK--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the ...

Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene ...

PATIENTS with factor VIII deficiency and prolonged skin bleeding time (von Willebrand's syndrome) who receive fresh blood or plasma from normal donors or from patients with hæmophilia A with very low ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe ...

THE separation of Factor VIII activity from fibrinogen is of considerable importance. From the therapeutic point of view it would seem desirable when treating haemophiliacs to use a protein fraction ...

We enrolled 85 of 121 eligible children. Overall, 37 subjects had DVT of which 25 were incident and 12 were prevalent (Fig. 1). Of the prevalent DVT, one was in the lower extremity unrelated to a CVC.

Setting: Two tertiary academic centers. Patients: We enrolled children younger than 18 years who were admitted to the PICU within 24 hours after insertion of a central venous catheter. We excluded ...